Press Release

Global Anti-Tuberculosis Therapeutics Market to grow with a CAGR of 5.90%.

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Anti-Tuberculosis Therapeutics Market.

According to TechSci Research report, “Global Anti-Tuberculosis Therapeutics Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Anti-Tuberculosis Therapeutics Market has valued at USD 1320.50 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.90% through 2028. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

Epidemiological shifts drive the demand for global anti-tuberculosis (TB) therapeutics. Changes in the epidemiology of TB have a significant impact on the demand for TB drugs and treatment strategies. As TB epidemiology evolves, new regions or countries may emerge as TB hotspots with high TB incidence rates. These areas often require increased resources for TB diagnosis, treatment, and control, leading to greater demand for anti-TB medications. Urbanization and population movement can lead to shifts in TB epidemiology. Rapidly growing urban areas may experience higher TB transmission rates, requiring enhanced TB control efforts and access to therapeutics. In some regions, aging populations may experience higher rates of TB reactivation due to waning immunity. This demographic shift can result in increased demand for TB therapeutics among older adults. Countries with the highest TB burdens often have the greatest demand for anti-TB therapeutics. Targeted interventions, funding, and access to medications are essential to manage and reduce the disease burden in these countries. Advances in genomic epidemiology allow for the tracking of TB strains and transmission patterns. This information helps identify high-risk populations and guides targeted interventions, including the provision of TB medications.

Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on " Global Anti-Tuberculosis Therapeutics Market

Tuberculosis (TB) is an infectious disease that primarily affects the lungs but can also extend to other organs like the spine and brain. It is caused by Mycobacterium tuberculosis, a type of bacteria. Pharmaceutical companies are intensifying their research to develop drugs that can shorten treatment duration and address the challenges posed by drug-susceptible and drug-resistant TB. Treatment for TB can be categorized into first-line, second-line, and drug-resistant treatments.

In March 2022, as part of its commitment to the Corporate TB Pledge, a joint initiative with the Central TB Division, Ministry of Health and Family Welfare in India, and United States Agency for International Development (USAID), Johnson & Johnson India announced the launch of a youth-focused, digital-first initiative #BeTheChangeForTB. This initiative supports the Indian Government's goal to end TB. The #BeTheChangeForTB program targets young people in India since they are most suited to lead the public in changing their behaviors, which would help to dramatically scale-up the battle against tuberculosis. The project will also dispel popular myths about TB and provide the correct information on the diagnosis and treatment of the illness. The initiative's communication and social mobilization components would involve a variety of online and offline activities, as well as collaboration with state and district health agencies, the National Tuberculosis Elimination Program (NTEP), and local neighborhoods.

Co-infection with HIV (Human Immunodeficiency Virus) is a significant challenge in the global anti-tuberculosis (TB) therapeutics market. HIV weakens the immune system, making individuals more susceptible to TB infection. HIV-infected individuals are at a much higher risk of developing active TB disease if they are exposed to TB bacteria. TB and HIV often present with similar symptoms, such as cough, fever, and weight loss. This can lead to delayed diagnosis and treatment for both diseases, as healthcare providers may not immediately recognize the possibility of co-infection. Treating co-infected individuals can be challenging due to potential drug interactions between anti-TB medications and antiretroviral therapy (ART) used to manage HIV. Some TB drugs, particularly rifampin, can interfere with the effectiveness of certain HIV medications. Co-infected individuals often require complex treatment regimens that simultaneously address both TB and HIV. These regimens must be carefully managed to ensure treatment effectiveness while minimizing adverse effects and drug interactions.

Global Anti-Tuberculosis Therapeutics Market segmentation is based on Disease Type, Diagnostic and Treatment, End User, and Region.

Based on Disease Type, Global Anti-Tuberculosis Therapeutics Market is segmented into Active TB, Latent TB, and Others. Latent tuberculosis infection (LTBI), often referred to as latent TB, is a condition in which an individual has been infected with the bacterium Mycobacterium tuberculosis but does not currently exhibit active symptoms of tuberculosis disease. Instead, the TB bacteria remain dormant or latent within the body. Individuals with latent TB do not feel sick and do not experience the typical symptoms of active TB, such as cough, chest pain, fever, night sweats, and weight loss. They generally appear healthy and cannot spread TB to others. Latent TB represents an infection with M. tuberculosis, but the immune system successfully contains the bacteria. It is not a form of active TB disease. A diagnosis of latent TB is typically confirmed through a positive reaction to a TB skin test (tuberculin skin test, TST) or a blood test called an interferon-gamma release assay (IGRA). These tests detect the presence of TB-specific proteins or antigens in the body.

Based on Region, North America dominated the Global Anti-Tuberculosis Therapeutics Market. North America's relatively low TB burden is partly due to rigorous TB control measures. However, the region's high levels of international travel and migration mean that TB remains a concern, and robust control efforts are in place to prevent its spread. North America has well-developed healthcare infrastructure, including access to state-of-the-art diagnostic tools and treatments. This enables early detection and effective treatment of TB cases. Clinical trials for new anti-TB drugs often include North American sites, and the U.S. Food and Drug Administration (FDA) plays a critical role in drug approvals. Successful clinical trials and drug approvals contribute to the global TB treatment arsenal.

Asia-pacific region to fastest growth in the Global Anti-Tuberculosis Therapeutics Market. The APAC region has a significant burden of TB cases, with several countries reporting high TB incidence rates. This high prevalence of TB creates a substantial demand for anti-TB therapeutics, including drugs and treatment regimens. APAC is the most populous region in the world, with a large and diverse population. The sheer number of people in the region means that even a moderate TB incidence rate can result in a substantial number of TB cases, driving the demand for TB therapeutics. Many countries in APAC are investing in expanding and improving their healthcare infrastructure. This includes strengthening diagnostic capabilities, expanding access to healthcare services, and enhancing the availability of TB medications. Some countries in the APAC region, such as India and China, have experienced rapid economic growth in recent years. This has led to increased healthcare spending and greater access to TB treatment for their populations.

Some of the major companies operating in the Global Anti-Tuberculosis Therapeutics Market include:

  • AstraZeneca Plc.
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

 

Download Free Sample Report

Customers can also request 10% free customization on this report

“Certain areas, particularly in North America, are projected to exert significant demand for Tuberculosis treatment. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Anti-Tuberculosis Therapeutics Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Anti-Tuberculosis Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Disease Type (Active TB, Latent TB, Others), by Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others), by End User (Hospitals, Specialty Clinics, Homecare, others), by region, and Competition evaluated the future growth potential of Global Anti-Tuberculosis Therapeutics Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Anti-Tuberculosis Therapeutics Market.

Contact

Techsci Research LLC

420 Lexington Avenue

Suite 300, New York

United States- 10170

M: +13322586602

Email: [email protected]

Web:  https://www.techsciresearch.com

Relevant News